Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
ALPINE IMMUNE SCIENCES, INC. (NVLS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/10/2021 |
8-K
| Quarterly results |
| 03/18/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results |
| 08/11/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results |
| 03/30/2020 |
8-K
| Quarterly results |
| 11/13/2019 |
8-K
| Quarterly results |
| 08/13/2019 |
8-K
| Quarterly results|
Docs:
|
"Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial Results ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 SEATTLE, WA - August 13, 2019 - Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2019. “I am proud of the progress Alpine has made in the first six months of the year and the momentum we’ve built heading into a potentially transformative year ahead,” said Mitchell H. Gold, MD, Executive Chairman and Chief Executiv..." |
|
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results - Alpine transitions to clinical-stage company - Completed financing to fund further development of both lead programs SEATTLE, WA - May 9, 2019 - Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2019. “The first quarter of 2019 was a significant one for Alpine as we transitioned into a clinical stage company by initiating the first-in-human Phase I study of our lead autoimmune/inflammatory disease program ALPN-101,” said Mitchell H. Gold, MD, Executive Chairman an..." |
|
| 03/18/2019 |
8-K
| Quarterly results|
Docs:
|
"Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results – First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 – Completed $25 Million Private Placement – Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients SEATTLE, WA - March 18, 2019 - Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today provided a corporate update and reported financial results for the year ended December 31, 2018. “This was a year of continued execution for Alpine as we transitioned from a preclinical company to a development stage company, dosing earlier thi..." |
|
| 11/08/2018 |
8-K
| Quarterly results|
Docs:
|
"Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results SEATTLE, WA - November 8, 2018 - Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2018. “We have had a highly productive quarter as we continue to rapidly advance our two lead programs, ALPN-101 for the treatment of autoimmune/inflammatory disease and ALPN-202 for oncology, toward our first human clinical trials,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. “We are excited by the strong cadence of preclinical data to be presented at upcoming..." |
|
| 05/14/2018 |
8-K
| Quarterly results|
Docs:
|
"Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results SEATTLE, WA — May 14, 2018 — Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2018. “We are increasingly encouraged by our promising preclinical results, which demonstrate the potential of our platform to change the way we approach and treat both cancer and autoimmune/inflammatory diseases,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. “We continue to make progress on our lead programs and remain ..." |
|
| 11/13/2017 |
8-K
| Quarterly results |
| 05/01/2017 |
8-K
| Form 8-K - Current report |
| 02/13/2017 |
8-K
| Form 8-K - Current report |
| 11/07/2016 |
8-K
| Quarterly results |
| 08/01/2016 |
8-K
| Form 8-K - Current report |
| 05/02/2016 |
8-K
| Form 8-K - Current report |
| 02/29/2016 |
8-K
| Quarterly results |
| 11/02/2015 |
8-K
| Quarterly results |
| 08/03/2015 |
8-K
| Quarterly results |
|
|